Impact of the International Consensus Classification of myelodysplastic syndromes. (28th December 2022)

• Record Type: Journal Article
• Authors: Zhang, Yudi; Wu, Junying; Xu, Zefeng; Qin, Tiejun; Qu, Shiqiang; Pan, Lijuan; Wang, Huijun; Sun, Qi; Li, Chengwen; Jia, Yujiao; Cai, Wenyu; Yan, Xin; Gong, Jingye; Gao, Qingyan; Li, Bing; Gale, Robert Peter; Xiao, Zhijian
• Is Part Of: British journal of haematology. Volume 201:Number 3(2023)
• Page Start: 443
• Page End: 448
• Publication Date: 2022-12-28
• Subjects: International Consensus Classification -- myelodysplastic syndromes -- prognostic -- World Health Organization classification; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.18628
• Languages: English
• ISSNs: 0007-1048

Abstract

Summary: The impact of the 2022 International Consensus Classification (ICC) of myelodysplastic syndromes (MDS) needs study. We analysed data from 989 MDS subjects classified using the 2016 World Health Organization (WHO) criteria to determine the impact of the new proposal. Our analyses suggested the ICC criteria of MDS‐SF3B1 identifies a more homogenous disease entity than the WHO 2016 criteria of myelodysplastic syndromes with ring sideroblasts (MDS‐RS). MDS, not otherwise specified with single lineage dysplasia (MDS, NOS‐SLD) patients had a better prognosis than MDS, NOS with multilineage dysplasia (MDS, NOS‐MLD) patients. MDS with mutated TP53 and MDS/acute myeloid leukaemia with mutated TP53 patients had the briefest survivals. These data support the ICC of MDS, which allows more accurate diagnoses and risk stratification.